FISH diagnostics in hematological malignancies;FISH-Diagnostik bei hämatologischen Neoplasien

LaboratoriumsMedizin

Volumn 29, Issue 5, 2005, Pages 335-342

  Schoch, Claudia ^a   Kern, Wolfgang ^a   Schnittger, Susanne ^a   Haferlach, Torsten ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

Acute lymphoblastic leukemia (ALL); Acute myeloid leukemia (AML); Chronic lymphatic leukemia (CLL); Chronic myeloid leukemia (CML); Comparative genomic hybridization (CGH); Fluorescence in situ hybridization (FISH); Myelodysplastic syndrome (MDS)

Indexed keywords

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CANCER GENETICS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENE TRANSLOCATION; GENETIC ANALYSIS; GENETIC PROCEDURES; HEMATOLOGIC MALIGNANCY; HUMAN; MOLECULAR PROBE; MYELODYSPLASIA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA;

EID: 27244459309     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1515/JLM.2005.047     Document Type: Article

References (31)

1. Verma RS, Bau A. Human Chromosomes, Principles and Techniques. New York (USA): McGraw-Hill, 1995.
2. Speicher MR, Ward DC. The coloring of cytogenetics. Nat Med 1996;2:1046-8.
3. Speicher MR, Ballard SG, Ward DC. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet 1996;12:368-75.
4. Schröck E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, et al. Multicolor spectral karyotyping of human chromosomes. Science 1996;273:494-7.
5. Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D, Gray JW, Waldman FM, et al. Comparative genomic hybridiza-tion for molecular cytogenetic analysis of solid tumors. Science 1992;258:818-21.
6. Kallioniemi O-P, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes, Chromosomes Cancer 1994;10:231-43.
7. Bloomfield CD. Prognostic factors for selecting curative therapy for adult acute myeloid leukemia. Leukemia 1992;6:65-7.
8. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
9. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al., on behalf of the Medical Research Council Adult and Children's Leukemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322-33.
10. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al., on behalf of the Medical Research Council Adult and Children's Leukemia Working Parties. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 2001;98:1312-20.
11. Schoch C, Haferlach T. Cytogenetics in acute myeloid leukemia. Curr Oncol Rep 2002;4:390-7.
12. Schoch C, Schnittger S, Kern W, Lengfelder E, Loffler H, Hiddemann W, et al. Rapid diagnostic approach to PMLRARalpha-positive acute promyelocytic leukemia. Hematol J 2002;3:259-63.
13. Brunning RD, Matutes E, Harris NL, Flandrin G, Vardiman J, Bennett JM, et al. Acute myeloid leukemia. In: Jaffe ES, Harris NL, Stein H, Vardiman J, editors. World Health Organization of Tumors, Pathology & Genetics, Tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001:75-108.
14. Schoch C, Haferlach T, Bursch S, Gerstner D, Schnittger S, Dugas M, et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: A detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes, Chromosomes Cancer 2002;35:20-9.
15. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998;91:3995-4019.
16. Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantravahi R, Block AW, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: The Cancer and Leukemia Group B experience. Blood 1999;93:3983-93.
17. Rubnitz JE, Pui C-H, Downing JR. The role of TEL fusion genes in pediatric leukemias. Leukemia 1999;13:6-13.
18. Wlodarska I, Mecucci C, Baens M, Marynen P, van den Berghe H. ETV6 gene rearrangements in hematopoietic malignant disorders. Leuk Lymphoma 1996;23:287-95.
19. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: A study on 350 cases. Leukemia 2002;16:53-9.
20. Kantarjian H, Sawyers CL, Hochhaus A, Guilhot F, Schiffer CA, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
21. Dewald GW, Brockman SR, Paternoster SF, Bone ND, O'Fallon JR, Allmer C, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003;121:287-95.
22. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
23. Stilgenbauer S, Bullinger L, Benner A, Wildenberger K, Bentz M, Dohner K, et al. Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia. Leukemia 1999;13:1331-4.
24. Martin-Subero JI, Gesk S, Harder L, Grote W, Siebert R. Interphase cytogenetics of hematological neoplasms under the perspective of the novel WHO classification. Anticancer Res 2003;23:1139-48.
25. Siebert R, Weber-Matthiesen K. Fluorescence in situ hybridization as a diagnostic tool in malignant lymphomas. Histochem Cell Biol 1997;108:391-402.
26. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
27. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546-58.
28. Ho PJ, Campbell LJ, Gibson J, Brown R, Joshua D. The biology and cytogenetics of multiple myeloma. Rev Clin Exp Hematol 2002;6:276-300.
29. Shaughnessy J Jr., Tian E, Sawyer J, McCoy J, Tricot G, Jacobson J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol 2003;120:44-52.
30. Zojer N, Konigsberg R, Ackermann J, Fritz E, Dallinger S, Kromer E, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000;95:1925-30.
31. Konigsberg R, Zojer N, Ackermann J, Kromer E, Kittler H, Fritz E, et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J Clin Oncol 2000;18:804-12.